Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Portfolio Pulse from Vandana Singh
Gilead Sciences Inc (NASDAQ:GILD) announced positive interim results from the ASSURE study for seladelpar, a treatment for primary biliary cholangitis (PBC). The study showed improvements in disease markers and pruritus with no serious adverse events. A New Drug Application for seladelpar has been accepted for priority review by the FDA, with a decision expected in August 2024.
May 20, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences announced positive interim results from the ASSURE study for seladelpar, showing improvements in PBC disease markers and pruritus. The FDA has accepted a New Drug Application for priority review, with a decision expected in August 2024.
The positive interim results from the ASSURE study for seladelpar indicate potential efficacy in treating PBC, which could lead to future revenue growth. The FDA's priority review acceptance further boosts the potential for market approval, positively impacting GILD's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100